| Alisertib |
MLN8237
|
AURORA A, MYCN
|
Mitosis
|
Phase 1, 2, 3
|
|
Selleck Chemicals
|
S1133
|
| Alvespimycin |
17-DMAG
|
HSP90
|
Chaperone protein folding
|
Phase 1, 2
|
|
Sigma-Aldrich
|
D5193
|
| BLU.9931 |
|
FGFR4
|
FGFR4/FGF19 signaling
|
Preclinical
|
|
Gift from Blueprint
|
|
| Bortezomib |
Velcade
|
Proteasome
|
Protein degradation
|
Approved
|
Phase 2
|
Selleck Chemicals
|
S1013
|
| Brivanib |
BMS-540215
|
VEGFR1, 2 and 3, FGFR1, 2 and 3
|
Tyrosine kinases
|
Phase 1, 2, 3
|
Phase 3
|
Selleck Chemicals
|
S1084
|
| Cabozantinib |
XL184, BMS-907351
|
VEGFR2, c-MET
|
Tyrosine kinases
|
Approved
|
Approved
|
Selleck Chemicals
|
S1119
|
| CD532 |
|
AURORA A, MYCN
|
Mitosis
|
Preclinical
|
|
Calbiochem
|
532605
|
| Dasatinib |
BMS-354825
|
SRC, ABL
|
Tyrosine kinases
|
Approved
|
Phase 2
|
Selleck Chemicals
|
S1021
|
| Decitabine |
5-Aza-2_-deoxycytidine
|
DNA methyltransferase
|
DNA metylation
|
Approved
|
|
ApexBio Technology
|
A1906
|
| Doxorubicin |
Adriamycin, NSC123127
|
DNA topoisomerase II
|
DNA replication
|
Approved
|
Approved
|
Selleck Chemicals
|
S1208
|
| Entinostat |
MS-275
|
HDAC1/3
|
Epigenetic erasers
|
Phase 1, 2
|
Phase 1
|
Selleck Chemicals
|
S1053
|
| ICG.001 |
|
CBP
|
Wnt/_-catenin signaling
|
Phase 1
|
|
Selleck Chemicals
|
S2662
|
| JNJ.38877605 |
|
c-MET
|
MET signaling
|
Phase 1
|
|
Selleck Chemicals
|
S1114
|
| Lenvatinib |
E7080
|
VEGFR2, VEGFR3, VEGFR1, PDGFR, FGFR1
|
Tyrosine kinases
|
Approved
|
Approved
|
Selleck Chemicals
|
S1164
|
| Linsitinib |
OSI-906
|
IGF-1R
|
Insulin growth factor signaling
|
Phase 1, 2
|
Phase 2
|
Selleck Chemicals
|
S1091
|
| MK.2206 |
|
AKT1/2/3
|
PI3K-AKT-mTOR signaling
|
Phase 1, 2
|
Phase 2
|
Selleck Chemicals
|
S1078
|
| Navitoclax |
ABT-263
|
BCL-2
|
Apoptosis
|
Phase 1, 2
|
|
Selleck Chemicals
|
S1001
|
| Nutlin.3 |
|
MDM2
|
P53 signaling
|
Phase 1
|
|
Selleck Chemicals
|
S1061
|
| Paclitaxel |
Taxol, NSC125973
|
Microtubule stabilizer
|
Mitosis
|
Approved
|
Phase 2
|
Selleck Chemicals
|
S1150
|
| PF.04691502 |
PF4691502
|
PI3K, mTOR
|
PI3K-AKT-mTOR signaling
|
Phase 1, 2
|
|
Selleck Chemicals
|
S2743
|
| PHA.665752 |
|
c-MET
|
MET signaling
|
Preclinical
|
|
Selleck Chemicals
|
S1070
|
| Rapamycin |
Sirolimus
|
mTOR (mTORC1/mTORC2)
|
PI3K-AKT-mTOR signaling
|
Phase 1, 2, 3
|
Phase 2
|
Selleck Chemicals
|
S1039
|
| Refametinib |
BAY 86-9766
|
MEK1/2
|
MAPK/ERK signaling
|
Phase 1, 2
|
Phase 2
|
Selleck Chemicals
|
S1089
|
| Regorafenib |
BAY 73-4506
|
VEGFR1/2/3, PDGFRB, KIT, RET, RAF1
|
Tyrosine kinases
|
Approved
|
Approved
|
Selleck Chemicals
|
S1178
|
| Resminostat |
RAS2410
|
HDAC1/3/6
|
Epigenetic erasers
|
Phase 1, 2
|
Phase 2
|
Selleck Chemicals
|
S2693
|
Codebase Soc. Coop.